Grants

Illinois Environmental Protection Agency

Environmental grant programs supporting water quality improvement, brownfield redevelopment, pollution prevention, and clean energy initiatives in Illinois.

$50K – $1M

EnvironmentalconservationCommunity Development

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Housing Development Authority (IHDA) — Housing & Community Development Grants

HousingCommunity Development

Illinois Housing Development Authority (IHDA)

Illinois Housing Development Authority (IHDA) provides grants and financing for affordable housing development, community development, homelessness prevention, and housing rehabilitation in IL.

$25K – $2M

Annual

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Housing Development Authority Grants

Illinois Housing Development Authority

Affordable housing grants and incentives for the development, preservation, and rehabilitation of affordable rental and homeownership housing across Illinois.

$200K – $2M

HousingCommunity DevelopmentEquity & Access

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Humanities Council Grants

Illinois Humanities Council

Grants for humanities programming including lectures, exhibitions, oral history, documentary, and public humanities projects in Illinois. Funded by NEH.

$1K – $20K

EducationArts & CultureCommunity Development

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Main Street Program

Illinois Historic Preservation Agency

Illinois Main Street supports downtown revitalization through four-point approach: design, promotion, economic vitality, and organization.

$5K – $50K

downtown revitalizationeconomic developmenthistoric preservation

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois MAP (Monetary Award Program)

financial aidscholarshipshigher education

Illinois Student Assistance Commission (ISAC)

State scholarship and financial aid program administered by Illinois Student Assistance Commission (ISAC) for IL students and educational institutions.

$500 – $7K

2026-10-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Perkins V CTE Grants

career technical educationworkforce developmentCTE

Illinois State Board of Education

Career and Technical Education funding under Perkins V for IL schools and colleges to strengthen CTE pathways, work-based learning, and industry certifications.

$25K – $600K

2026-09-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Preschool for All Expansion

early childhoodpre-kschool readiness

Illinois State Board of Education

Early childhood education grants supporting pre-K programs, childcare quality improvement, and school readiness initiatives in IL.

$50K – $600K

2026-07-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois State Board of Education Competitive Grants

Illinois State Board of Education

Competitive federal and state grants for Illinois school districts and educational organizations supporting student achievement, equity, and innovation in education.

$5K – $500K

EducationEquity & Accessinnovation

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois State Government Advocacy Services

Community DevelopmentHealth

JOHN J. MILLNER AND ASSOCIATES, INC.

Management and Business Professionals and Administrative Services

2026-11-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois STEM Learning Pathways

STEMscience educationtechnology education

Illinois State Board of Education

STEM education initiative grants for IL to expand science, technology, engineering, and mathematics programs in K-12 and postsecondary institutions.

$10K – $200K

2026-09-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Tool Works Foundation

ITW Foundation

Supports workforce development, STEM education, and community programs in ITW communities worldwide.

$10K – $250K

workforce developmentSTEM educationcommunity development

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Veterans Commission — Service Grants

veteran servicesstate programsHousing+1

Illinois Veterans Commission

State grants for veteran service programs in Illinois including housing, employment, education, and mental health support.

$10K – $100K

2026-09-01

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illinois Workforce Innovation Board — Workforce Development Grants

Illinois Workforce Innovation Board

Illinois Workforce Innovation Board administers workforce development grants funding job training, apprenticeships, incumbent worker training, and employer-based training programs in IL.

$10K – $500K

workforcetrainingeconomic_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illumina NovaSeq X Sequencing System

OD - NIH Office of the Director

Project Summary This grant application requests funds to acquire an Illumina NovaSeq X Sequencing System to support teams of well-funded biomedical researchers who are experienced in high throughout sequencing approach to conduct genomic analysis at the University of Texas Health at San Antonio (UTHSA). This instrument will be housed in the Genome Sequencing Facility (GSF) at the Greehey Children’s Cancer Research Institute (GCCRI), a campus-wide shared core facility operated by a team of well-trained and experienced staff and bioinformaticians specializing in sequencing and genomics technologies. Since its inception in 2011, the GSF, with a variety of high-throughput sequencing and genomic instruments, has become a critical component for genomic research and collaborations within UTHSA and across San Antonio region. Currently, high throughput sequencing is conducted on one Illumina NovaSeq 6000 and one NextSeq 2000 at GSF, and there are no other accessible NGS platforms within UTHSA or the surrounding San Antonio institutions. A wide array of basic, translational, clinical, and genomics studies at UTHSA depend on reliable access to a high-capacity, cost-effective sequencing platform supported by integrated bioinformatics analysis. The requested NovaSeq X Sequencing System will meet these requirements, thus enabling the GSF to provide cost effective, high-quality sequencing data to support NIH-funded biomedical research, benefiting 15 Major Users and 21 Other Users whose projects are in areas such as cancer, aging, pain management, immunology, diabetes, infectious disease, and neurodegenerative diseases, as outlined in this proposal. Our history and future planning demonstrate UTHSA’s strong commitment to advancing genomics research, fully supporting this grant application by providing the necessary resources for GSF's operation. Additionally, the new NovaSeq X System will enhance training opportunities for pre- and post-doctoral fellows, physicians, and young scientists, fostering excellence in genomics research and bioinformatics innovations at UTHSA and South Texas region. Thus, acquiring an Illumina NovaSeq X Sequencing System will significantly enhance the institution’s sequencing capacity, accelerate NIH-funded investigations, strengthen collaborative research, and contribute to improving health outcomes—particularly for the predominantly Hispanic population in South Texas.

Up to $750K

2027-05-14

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine

upcoming

National Institutes of Health

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose a program that supports integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of the pathogenesis and progression AD/ADRD.The proposed research projects will employ interdisciplinary approaches that integrate innovative techniques to dissect the genomic drivers of AD/ADRD. These projects will leverage advanced analytical methods, including machine learning and comparative genomic analysis across multiple genetic ancestries or multiple neurodegenerative diseases, along with cutting-edge tools like genome editing, functional characterization assays, and emerging single-cell and spatial omics technologies. These studies will use sophisticated disease models, such as human stem cell-based systems, ex vivo, and in vivo models that reflect different genetic ancestries, various model organisms, or multiple neurodegenerative conditions. These cross-ancestry, cross-disease, and cross-species approaches will enable a more comprehensive investigation of the genomic drivers of neurodegeneration and neuropathogenesis. Ultimately, this initiative may lead to the identification of actionable therapeutic targets for AD/ADRD, meeting the urgent need for mechanism-driven insights that can guide precision medicine approaches for its treatment.Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.

2026-10-06

Health

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine

upcoming

National Institutes of Health

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose a program that supports integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of the pathogenesis and progression AD/ADRD.The proposed research projects will employ interdisciplinary approaches that integrate innovative techniques to dissect the genomic drivers of AD/ADRD. These projects will leverage advanced analytical methods, including machine learning and comparative genomic analysis across multiple genetic ancestries or multiple neurodegenerative diseases, along with cutting-edge tools like genome editing, functional characterization assays, and emerging single-cell and spatial omics technologies. These studies will use sophisticated disease models, such as human stem cell-based systems, ex vivo, and in vivo models that reflect different genetic ancestries, various model organisms, or multiple neurodegenerative conditions. These cross-ancestry, cross-disease, and cross-species approaches will enable a more comprehensive investigation of the genomic drivers of neurodegeneration and neuropathogenesis. Ultimately, this initiative may lead to the identification of actionable therapeutic targets for AD/ADRD, meeting the urgent need for mechanism-driven insights that can guide precision medicine approaches for its treatment.Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.

2026-10-06

Healthhealthcare

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illuminating jumbo phage infection mechanisms: from complex prokaryotic cell biology to novel therapeutics

NIGMS - National Institute of General Medical Sciences

Project Summery/Abstract Amid a public health crisis driven by antibiotic-resistant pathogenic bacteria, bacteriophages (phages), which naturally infect and kill bacteria, represent a promising alternative as antimicrobials. However, a significant challenge is posed by diverse bacterial immune mechanisms that resist phage infections. Overcoming this obstacle requires phages equipped with robust anti-immune capabilities. In this context, ΦKZ-like jumbophages (genomes > 200kb) have an exceptional ability to counter various bacterial nucleolytic immune systems throughout infection, with numerous family members targeting key Gram-negative pathogens. The jumbophage ΦKZ is a broad host range killer of the multi-antibiotic-resistant pathogen Pseudomonas aeruginosa and serves as the leading model phage for this family. Immune evasion is largely achieved through the assembly of a bacterial membrane lipid derived compartment termed the “Early Phage Infection Vesicle” (EPIV), which I co-discovered during my postdoctoral work, and a phage-encoded proteinaceous compartment called the “phage nucleus,” which shields the replicating phage genome. The long term goal of this study is to understand three unexplored aspects of jumbophage biology related to the biogenesis and functioning of the EPIV. The EPIV houses early transcription, but the phage has to solve a fundamental challenge not previously solved in bacteria–mRNA export from a lipid-bound compartment and successful docking with ribosomes, which are unusually uncoupled from transcription in this case. I hypothesize that a novel mRNA export channel, analogous to the eukaryotic nuclear pore complex, is assembled by injected ΦKZ proteins to export mRNA to ribosomes. I will uncover this complex using cryo-ET, mass spectrometry and genetics. I will additionally examine the role of EPIV assembly in enabling ‘pseudolysogeny’ in jumbophage infections. This process of phage quiescence was observed in jumbophages long ago but lacks a mechanistic understanding. I hypothesize that the EPIV has the potential to be a stable pseudolysogenic entity inside an infected bacterium that I will test herein with my multidisciplinary approach. Finally, I will attempt to elucidate the mechanism of EPIV biogenesis – it remains entirely unknown how this massive membrane-bound organelle is rapidly assembled within bacteria and how its formation is conserved across diverse jumbophage infections. To answer these questions, I will combine genetic dissection and c-ET to reveal the key participants and early assembly events of this unique phage-driven prokaryotic organelle formation. Overall, my studies stand to uncover fundamentally fascinating bacterial-phage cell biology in addition to innovative and potentially transferable mechanisms to enhance phage success in combating pathogenic bacteria. This research will be conducted at UCSF, which hosts state-of-the-art facilities and a highly intellectual and collaborative research community. It will also provide me with the training in genetics and structural biology that I need to fulfill my postdoctoral training goals and pioneer an independent research program in bacterial-phage interactions.

Up to $123K

2028-04-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Illuminating Neuropeptide Modulation of Substance Abuse Withdrawal: Novel Photochemical Tools for Precision Control

NIDA - National Institute on Drug Abuse

Project Summary/Abstract Methamphetamine use disorder afflicts millions of Americans and precipitates a debilitating withdrawal syndrome marked by hypodopaminergia, anxiety, and somatic distress, yet our ability to interrogate its neuropeptidergic underpinnings is hindered by a lack of versatile, high precision chemical probes in neuroscience. We hypothesize that corticotropin releasing factor (CRF) mediates negative affect and stress responsivity, neuropeptide Y (NPY) promotes resilience within reward circuits, and orexin (ORX) governs motivational and somatic outputs during withdrawal. To test this, we will engineer a modular library of cyclic, photolabile caging scaffolds that render CRF, NPY, and ORX both inert and proteolysis resistant (enhancing in vivo stability and bioavailability), thereby enabling multiplexed interrogation of multiple peptide systems reducing the need to generate or maintain multiple mouse lines to modulate each peptidergic system. Each probe will undergo a rigorous validation pipeline: biophysical photolysis and binding assays to quantify release kinetics and receptor engagement, cell culture studies to confirm receptor specificity and downstream signaling, and acute brain slice experiments in both naïve and methamphetamine-withdrawn mice (focused uncaging on genetically identified cell types with whole cell electrophysiology and two photon calcium imaging) to verify functional efficacy and altered peptide responsiveness. We will then deploy genetically encoded peptide sensors to dynamically monitor CRF in the bed nucleus of the stria terminalis (BNST), NPY in the ventral tegmental area (VTA), and ORX in the nucleus accumbens (NAc) both before methamphetamine exposure and during withdrawal in behaving mice, an approach that will reveal how peptide activity in discrete circuits drives specific withdrawal features. Separate experiments using time locked uncaging manipulations will test causality by modulating peptide signal and assessing effects on withdrawal phenotypes. Behavioral endpoints will include quantitative somatic withdrawal scoring (for example, jumps and tremors), validated anxiety assays (elevated plus maze and open field), and reward related paradigms (sucrose preference and conditioned place preference), analyzed in both male and female mice to uncover sex specific peptide mechanisms. Because CRF, NPY, and ORX, along with their respective brain circuits, are conserved across mammals, these mechanistic insights will be directly relevant to human neurobiology and withdrawal physiology. Leveraging these findings will pave the way to rationally design peptide-based agonists and antagonists as prototype therapeutics to restore neuropeptide balance and ameliorate withdrawal symptoms. Finally, we will disseminate our chemical reagents, protocols, and data through open access repositories, empowering the broader neuroscience community to apply these spatiotemporal control strategies across diverse research domains and accelerate development of targeted treatments for substance use disorders.

Up to $462K

2031-04-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

ILO Regular Budget Supplementary Account (RBSA)

ILO

Supports decent work programs in developing countries including employment promotion, social protection, labor standards, and workplace safety.

$50K – $500K

laboremploymentsocial protection+1

Free to search & build · $99 one-time to unlock the application pack · No subscription

Image-Based Modeling of Pediatric Charcot-Marie-Tooth Disease Relative to Neuromuscular Development and Treatment

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

PROJECT SUMMARY Charcot Marie Tooth disease (CMT) is a progressive neurologic disease that causes a characteristic cavovarus foot deformity associated with pain, decreased ambulation, and escalating disability. CMT primarily presents in children and adolescents, but lack of objective treatment algorithms limits the ability of adolescents with CMT to maintain independence and preserve mobility during their development and transition to adulthood. Variability in treatment planning is caused in part by the wide variability in presentation and poor characterization of foot structure and function across the spectrum of genetic subtypes that prevents objective decision-making about physical therapy, orthotic design, and surgical intervention to maximally protect mobility. While the deformity of CMT is believed to be caused by alignment change, recent research suggests that differences in bony morphology additionally contribute. Further, muscle strength is known to be decreased but muscle morphology has not been studied in CMT and the variability of foot symptoms in CMT is not currently linked to specific genetic subtypes or foot shape. The main objective of this study is to characterize bone morphology across genetic subtype and treatment conditions and to investigate the relationships between bone morphology, muscle morphology, and functional outcomes in adolescents with CMT. In Aim 1, I will utilize statistical shape modeling (SSM) from retrospectively collected weight-bearing computed tomography (WBCT) datasets to evaluate differences in bony morphology and foot alignment between genetic subtypes of CMT. I will further analyze differences in foot structure with use of ankle-foot orthoses or following surgical correction of cavovarus deformity. In Aim 2, I will expand this modeling technique to image data from WBCT and magnetic resonance imaging (MRI) to create combined SSMs of bone and muscle morphology. I will then use these models to analyze differences in morphology relative to genetic subtype and age and to correlate morphology with muscle strength and functional ability. Together, these aims will contribute to a better understanding of CMT-associated foot and ankle deformity to ultimately improve treatment planning for this complex population. My interdisciplinary team of mentors will provide training in medical imaging, computational modeling, and pediatric human-subjects research, complemented by clinical mentorship and shadowing in orthopaedics, neurology, and rheumatology. The training plan was developed in collaboration with my Sponsors to address my primary goals of conducting independent, collaborative human-subjects research; advancing communication and grant-writing skills; learning mentoring and leadership; and honing clinical skills. This training is ideal for a future physician-scientist with the goal of improving patient care in pediatric neuromusculoskeletal medicine.

Up to $55K

2030-02-28

Free to search & build · $99 one-time to unlock the application pack · No subscription

Image-guided adaptable CAR T cell therapy for solid tumors

NCI - National Cancer Institute

PROJECT SUMMARY Despite promising results in treating B cell malignancies, over 50% of patients undergoing chimeric antigen receptor (CAR) T cell therapy experience tumor relapse, and CAR T cells have not consistently shown effectiveness against solid tumors. Antigen escape, T cell exhaustion, and severe toxicities remain major obstacles. This proposal addresses these challenges by developing an image-guided, universal, adaptable CAR (A-CAR) system comprising a tumor-targeting adaptor molecule fused with a C-terminal tag and a tag-specific CAR on T cells. Our stepwise approach to image-guided CAR T cell therapy involves: (1) Imaging: PET assessment of adaptor biodistribution using radiolabeled VHH adaptors; (2) Treatment: a single infusion of autologous tag-specific CAR T cells with optimized VHH adaptors that coat tumor cells for CAR T recognition; and (3) Assessment: monitoring tumor response and CAR T distribution via ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT. The clinically approved radiotracer ⁶⁸Ga-DOTATATE tracks CAR T cell expansion and activity at on- and off-tumor sites through binding to somatostatin receptor 2 (SSTR2) co-expressed on CAR T cells. The high specificity, affinity, and favorable kinetics of VHHs make them ideal for PET imaging and as CAR T cell adaptors, enabling non-invasive detection of antigen expression, patient selection, and prediction of homing sites and offtumor toxicity prior to treatment. This project comprehensively investigates VHHs as CAR T adaptors, including pharmacokinetic and biodistribution characterization, optimization of delivery (intermittent cyclic tumor tagging vs. continuous infusion) and dosing, and the potential to mitigate T cell exhaustion and overcome antigen escape through multi-antigen targeting. Mouse xenograft and syngeneic tumor models are essential for this work, as they are the only systems in which VHH adaptor biodistribution, CAR T cell trafficking, tumor targeting, and toxicity can be evaluated together in a living organism. These in vivo models enable optimization of adaptor and CAR T dosing, assessment of antigen escape and exhaustion under physiological conditions, and validation of PET imaging as a predictive tool — none of which are achievable in cell culture. By refining VHH and CAR T delivery guided by quantitative imaging, we seek to enhance efficacy and minimize off-tumor toxicity, with the ultimate goal of advancing A-CAR therapy against solid cancers.

Up to $415K

2027-07-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Image-Guided Cancer Interventions (SBIR [R43/R44])